BioArctic AB (publ) (BRCTF)
OTCMKTS · Delayed Price · Currency is USD
19.34
0.00 (0.00%)
Jul 30, 2025, 8:00 PM EDT
BioArctic AB Employees
BioArctic AB had 107 employees as of December 31, 2024. The number of employees increased by 19 or 21.59% compared to the previous year.
Employees
107
Change (1Y)
19
Growth (1Y)
21.59%
Revenue / Employee
$1,303,112
Profits / Employee
$774,619
Market Cap
1.91B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 107 | 19 | 21.59% |
Dec 31, 2023 | 88 | 27 | 44.26% |
Dec 31, 2022 | 61 | 12 | 24.49% |
Dec 31, 2021 | 49 | 4 | 8.89% |
Dec 31, 2020 | 45 | 3 | 7.14% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo, Inc. | 3,116 |
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
American Oncology Network | 1,914 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
Silence Therapeutics | 116 |
BioArctic AB News
- 12 days ago - Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 - PRNewsWire
- 18 days ago - The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association - PRNewsWire
- 5 weeks ago - BioArctic: Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize - PRNewsWire
- 7 weeks ago - BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - PRNewsWire
- 2 months ago - BioArctic's Capital Markets Day 2025 - entering a new era of growth - PRNewsWire
- 2 months ago - Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) - PRNewsWire
- 2 months ago - Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET - PRNewsWire
- 3 months ago - Exidavnemab phase 2a study expanded to include MSA patients - PRNewsWire